[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595931":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":188,"collaborators":20,"id":190,"slug":191,"hasResults":192,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":192,"sex":198,"minAge":199,"maxAge":20,"enrollmentInfo":200,"targetDuration":20,"studyType":203,"phases":204,"briefSummary":206,"conditions":207,"keywords":213,"overallStatus":218,"whyStopped":20,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":228},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Screening group","EXPERIMENTAL","This screening study focuses on Mongolian patients living in France. Screening will be organised in 11 centres in France, with 1 to 3 screening sessions per centre: patients will be informed of these screening sessions by the Mongolian Embassy in France, social networks and communities.\n\nScreening will be carried out by Rapid Diagnostic Orientation Test (TRODS) for hepatitis B (HBV), hepatitis C (HCV) and hepatitis B (HCV). If the TRODs are positive, a confirmatory serology test will be carried out, followed by specialist hepatology treatment.",[13],"Diagnostic Test: Community screening for hepatitis B, C and delta in the Mongolian population living in France",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Community screening for hepatitis B, C and delta in the Mongolian population living in France","Screening will be organised in 11 centres in France, with 1 to 3 screening sessions per centre: patients will be informed of these screening sessions by the Mongolian Embassy in France, social networks and communities.\n\nDuring this screening visit, Rapid Diagnostic Orientation Test (RDOT) will be carried out to screen for HBV and HCV. If the RDOT is negative for both viruses, an information on transmission and prevention of viral infection will be given.\n\nIf the RDOT is positive, confirmation of these tests by blood sampling will be organized and complementary biology (ASAT, ALAT, GGT, PAL, bilirubin total, bilirubin conjugated). If HBV RDOT positive, additional tubes will be collected for centralized analysis at the end of the study (VHD DNA, VHD genotyping, fibrotest and LCR1\u002F2 test).\n\nOnce these confirmatory tests have been carried out, the patient will be referred to a hepatology consultation.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"François BAILLY, Dr","CONTACT","+33 4 26 73 27 33","francois.bailly@chu-lyon.fr",[28,46,60,75,90,104,118,132,146,160,174],{"facility":29,"status":20,"city":30,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Centre Hospitalier Annecy Genevois","Annecy","France","FR",{"type":34,"coordinates":35},"Point",[36,37],6.12565,45.90878,{"lat":37,"lon":36},[40,44],{"name":41,"role":24,"phone":42,"phoneExt":20,"email":43},"Frederic HELUWAERT, Dr","+33 4 50 63 63 07","fheluwaert@ch-annecygenevois.fr",{"name":41,"role":45,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":47,"status":20,"city":48,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Centre Expert Hépatites Virales Aquitaine, CHU de Bordeaux","Bordeaux",{"type":34,"coordinates":50},[51,52],-0.58046,44.84124,{"lat":52,"lon":51},[55,59],{"name":56,"role":24,"phone":57,"phoneExt":20,"email":58},"Juliette Foucher, Dr","+33 5 57 65 64 39","juliette.foucher@chu-bordeaux.fr",{"name":56,"role":45,"phone":20,"phoneExt":20,"email":20},{"facility":61,"status":20,"city":62,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"CHU de Clermont Ferrand","Clermont-Ferrand",{"type":34,"coordinates":64},[65,66],3.08682,45.77969,{"lat":66,"lon":65},[69,73],{"name":70,"role":24,"phone":71,"phoneExt":20,"email":72},"Armand ABERGEL, Pr","+33 4 73 75 05 23","aabergel@chu-clermontferrand.fr",{"name":74,"role":45,"phone":20,"phoneExt":20,"email":20},"Armand Abergel, Pr",{"facility":76,"status":20,"city":77,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Hôpital Henri Mondor - Assistante Publique Hopitaux de Paris (APHP)","Créteil",{"type":34,"coordinates":79},[80,81],2.46569,48.79266,{"lat":81,"lon":80},[84,88],{"name":85,"role":24,"phone":86,"phoneExt":20,"email":87},"Vincent LEROY, Pr","+33 1 49 81 23 25","vincent.leroy2@aphp.fr",{"name":89,"role":45,"phone":20,"phoneExt":20,"email":20},"Vincent Leroy, Pr",{"facility":91,"status":20,"city":92,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"CHU Grenoble Alpes","Grenoble",{"type":34,"coordinates":94},[95,96],5.71479,45.17869,{"lat":96,"lon":95},[99,103],{"name":100,"role":24,"phone":101,"phoneExt":20,"email":102},"Marie Noelle Hilleret, Dr","+33 4 76 76 62 57","MNHilleret@chu-grenoble.fr",{"name":100,"role":45,"phone":20,"phoneExt":20,"email":20},{"facility":105,"status":20,"city":106,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"CHRU Lille","Lille",{"type":34,"coordinates":108},[109,110],3.05512,50.63391,{"lat":110,"lon":109},[113,117],{"name":114,"role":24,"phone":115,"phoneExt":20,"email":116},"Philippe MATHURIN, Pr","+33 3 20 44 55 97","p-mathurin@chru-lille.fr",{"name":114,"role":45,"phone":20,"phoneExt":20,"email":20},{"facility":119,"status":20,"city":120,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Service d'Hépatologie, Institut d'hépatologie de Lyon, Hôpital Croix-Rousse, Hospices Civils de Lyon","Lyon",{"type":34,"coordinates":122},[123,124],4.84789,45.74906,{"lat":124,"lon":123},[127,131],{"name":128,"role":24,"phone":129,"phoneExt":20,"email":130},"Mahé RAFFIN","+33 4 26 73 27 38","mahe.raffin@chu-lyon.fr",{"name":23,"role":45,"phone":20,"phoneExt":20,"email":20},{"facility":133,"status":20,"city":134,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"CHRU Rennes Pontchaillou","Rennes",{"type":34,"coordinates":136},[137,138],-1.67431,48.11109,{"lat":138,"lon":137},[141,145],{"name":142,"role":24,"phone":143,"phoneExt":20,"email":144},"Caroline Jezequel, Dr","+33299284298","caroline.jezequel@chu-rennes.fr",{"name":142,"role":45,"phone":20,"phoneExt":20,"email":20},{"facility":147,"status":20,"city":148,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"CHU de Rouen","Rouen",{"type":34,"coordinates":150},[151,152],1.09932,49.44313,{"lat":152,"lon":151},[155,159],{"name":156,"role":24,"phone":157,"phoneExt":20,"email":158},"Ghassan Riachi, Dr","+33 2 32 88 66 33","Ghassan.Riachi@chu-rouen.fr",{"name":156,"role":45,"phone":20,"phoneExt":20,"email":20},{"facility":161,"status":20,"city":162,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Hôpitaux Universitaires de Strasbourg","Strasbourg",{"type":34,"coordinates":164},[165,166],7.74553,48.58392,{"lat":166,"lon":165},[169,173],{"name":170,"role":24,"phone":171,"phoneExt":20,"email":172},"Antonio SAVIANO, Dr","+33 3 69 55 16 04","antonio.saviano@chru-strasbourg.fr",{"name":170,"role":45,"phone":20,"phoneExt":20,"email":20},{"facility":175,"status":20,"city":176,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"CHRU Bretonneau","Tours",{"type":34,"coordinates":178},[179,180],0.70398,47.39484,{"lat":180,"lon":179},[183,187],{"name":184,"role":24,"phone":185,"phoneExt":20,"email":186},"Louis d'Alteroche, Dr","+33 2 47 47 59 16","L.DALTEROCHE@chu-tours.fr",{"name":184,"role":45,"phone":20,"phoneExt":20,"email":20},{"type":189,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100595931","community-screening-and-management-of-hepatitis-b-c-and-delta-in-the-mongolian-population-living-in-france-100595931",false,"NCT07038863","Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","Community Screening for Hepatitis B, C and Delta in the Mongolian Population Living in France","Mondelta","Inclusion Criteria:\n\n* Mongolian people\n* Over 15 years of age\n* Living in France\n* Majors agree to participate or minors whose parental guardians agree to their child's participation in the study\n\nExclusion Criteria:\n\n* People already followed for viral hepatitis, treated or not treated\n* Persons deprived of their liberty by a judicial or administrative decision\n* Adults subject to a legal protection measure (guardianship, curators)\n* People participate in any interventional research except routine care research (old regulation) and category 2 research that does not interfere with the primary endpoint analysis","ALL","15 Years",{"count":201,"type":202},2000,"ESTIMATED","INTERVENTIONAL",[205],"NA","In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce the morbidity and mortality of these patients. A study carried out in California in the Mongolian community found an HBV prevalence of 9.7% and positive HDV serology in 41% of these patients.\n\nThere is a large Mongolian community in France, estimated at between 5,000 and 6,000 patients. Although the majority of these patients are covered by French social security; however, access to care and screening for viral hepatitis often remain difficult and insufficient for migrant or vulnerable populations in France The aim of this study is to screen the Mongolian community in France for viral hepatitis, and then initiate a program of care and treatment.",[208,209,210,211,212],"HEPATITIS C (HCV)","Hepatitis B Virus (HBV)","Hepatitis D","Hepatocellular Carcinoma (HCC)","Liver Fibrosis",[214,215,216,217],"HBV","HCV","HDV","HCC","NOT_YET_RECRUITING","2025-06-18",{"date":221,"type":222},"2025-06-26","ACTUAL",{"date":224,"type":202},"2025-09-01",{"date":226,"type":202},"2028-05-01",{"name":5,"class":6},11]